Sechenov University completes first human-safety trial for COVID-19 vaccineJuly 13, 2020 0 By FM
The clinical trials of the COVID-19 vaccine conducted by the Sechenov First Moscow State Medical University, Russia have been successfully completed, reports said quoting Vadim Tarasov, the director of Sechenov’s Institute for Translational Medicine and Biotechnology.
In the clinical study at Sechenov University, the volunteers from both the sex, aged 18 to 65 received, a lyophilised vaccine.
The vaccine was developed by Gamaleya Institute, an epidemiology research centre in Moscow. The trial sanctioned by the Russian Ministry of Health began on 16 June at the Sechenov University.
The first group including 18 participants received the jab on 18 June 2020. The second group of 20 healthy volunteers received the vaccine on 23 June 2020 at the Practical Research Centre for Interventional Cardiovasology.
Some participants of the trial experienced headaches and elevated body temperature, however, these symptoms resolved completely within 24 hours after vaccine administration, noted the researchers.
The trial, which was conducted to show the vaccine’s safety on humans, was confirmed as successful, noted Alexander Lukashev, the director of the Institute of Medical Parasitology, Tropical, and Vector-Borne Diseases at Sechenov University.
The first group of volunteers are expected to be discharged on 15th July and the second on 20 July, stated Tarasov.